Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 28 June 1996:
Vol. 272. no. 5270, pp. 1882 - 1883
DOI: 10.1126/science.272.5270.1882
Prev | Table of Contents | Next

News

Jon Cohen

A new class of anti-HIV drugs called protease inhibitors offers the most promising therapy so far. In combination with other antiviral drugs, they can reduce virus loads to undetectable levels. The manufacturers of the two leading protease inhibitors, Merck and Abbott, took different routes but arrived at the finishing post at almost exactly the same time.

Read the Full Text

ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products